![Enfermedad actual ,[object Object],Factores de riesgo ,[object Object],Antecedentes ,[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Empfohlen
Empfohlen
Weitere ähnliche Inhalte
Was ist angesagt?
Was ist angesagt? (20)
Andere mochten auch
Andere mochten auch (20)
Ähnlich wie Ateneo 04 08-2010
Ähnlich wie Ateneo 04 08-2010 (20)
Mehr von nachirc
Ateneo 04 08-2010
- 1. Ateneo Central 04 de agosto de 2010 Dr. Roberto Larghi Servicio de Diagnostico y Tratamiento Endovascular
- 3. ECG ingreso
- 7. Cinecoronariografía Bolo e Infusión de Eptifibatide
- 8. Angioplastia Catéter de Tromboaspiración Diver
- 9. Angioplastia Stent Liberté® 3.0x28 mm- 16 ATM
- 10. Angioplastia
- 11. Angioplastia
- 12. Angioplastia Stent Liberté® 3.0x12 mm- 16 ATM
- 13. Angioplastia
- 14. Angioplastia
- 15. Angioplastia
- 16. ECG post APTC
- 19. ECG
- 21. Cinecoronariografía Bolo e Infusión de Eptifibatide
- 22. Angioplastia Catéter de Trombo aspiración Diver
- 23. Angioplastia Angioplastia simple Balón 3.5x 28 mm- 16 ATM
- 24. Angioplastia
- 25. Angioplastia
- 26. Angioplastia
- 28. Original Article N Engl J Med Volume 361(11):1045-1057 September 10, 2009
- 33. Características basales Wallentin L et al. N Engl J Med 2009;361:1045-1057
- 34. Wallentin L et al. N Engl J Med 2009;361:1045-1057
- 35. EP de eficacia (compuesto de MCV, IM o ACV)
- 36. EP mayores de eficacia
- 37. EP de eficacia secundarios
- 38. Stent Trombosis (para cualquier stent)
- 39. Wallentin L et al. N Engl J Med 2009;361:1045-1057 Tiempo al sangrado Mayor
- 42. Tiempo al Sangrado Mayor PLATO no relacionado al procedimiento
- 49. Muchas Gracias
Hinweis der Redaktion
- Table 1. Baseline Characteristics of the Patients, According to Treatment Group.
- Figure 1. Cumulative Kaplan-Meier Estimates of the Time to the First Adjudicated Occurrence of the Primary Efficacy End Point. The primary end point - a composite of death from vascular causes, myocardial infarction, or stroke - occurred significantly less often in the ticagrelor group than in the clopidogrel group (9.8% vs. 11.7% at 12 months; hazard ratio, 0.84; 95% confidence interval, 0.77 to 0.92; P<0.001).
- Figure 2. Cumulative Kaplan-Meier Estimates of the Time to the First Major Bleeding End Point, According to the Study Criteria. The time was estimated from the first dose of the study drug in the safety population. The hazard ratio for major bleeding, defined according to the study criteria, for the ticagrelor group as compared with the clopidogrel group was 1.04 (95% confidence interval, 0.95 to 1.13).